136 related articles for article (PubMed ID: 37751865)
1. Targeting Methionine Addiction of Cancer Cells with Methioninase.
Pokrovsky VS; Qoura LA; Demidova EA; Han Q; Hoffman RM
Biochemistry (Mosc); 2023 Jul; 88(7):944-952. PubMed ID: 37751865
[TBL] [Abstract][Full Text] [Related]
2. Methioninase Gene Therapy.
Hoffman RM; Miki K; Al-Refaie W; Xu M; Tan Y
Methods Mol Biol; 2019; 1866():173-197. PubMed ID: 30725416
[TBL] [Abstract][Full Text] [Related]
3. The potential of methioninase for cancer treatment.
Abo Qoura L; Balakin KV; Hoffman RM; Pokrovsky VS
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(4):189122. PubMed ID: 38796027
[TBL] [Abstract][Full Text] [Related]
4. Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer Treatment.
Kubota Y; Han Q; Aoki Y; Masaki N; Obara K; Hamada K; Hozumi C; Wong ACW; Bouvet M; Tsunoda T; Hoffman RM
Cancer Diagn Progn; 2023; 3(3):272-281. PubMed ID: 37168964
[TBL] [Abstract][Full Text] [Related]
5. Oral Installation of Recombinant Methioninase-producing
Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Baranov A; Bouvet M; Tsunoda T; Hoffman RM
Cancer Genomics Proteomics; 2022; 19(6):683-691. PubMed ID: 36316039
[TBL] [Abstract][Full Text] [Related]
6. Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer.
Miyake M; Miyake K; Han Q; Igarashi K; Kawaguchi K; Barangi M; Kiyuna T; Sugisawa N; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Bouvet M; Endo I; Hoffman RM
Biochem Biophys Res Commun; 2023 Feb; 643():48-54. PubMed ID: 36586158
[TBL] [Abstract][Full Text] [Related]
7. Pilot Phase I Clinical Trial of Methioninase on High-Stage Cancer Patients: Rapid Depletion of Circulating Methionine.
Hoffman RM; Tan Y; Li S; Han Q; Zavala J; Zavala J
Methods Mol Biol; 2019; 1866():231-242. PubMed ID: 30725419
[TBL] [Abstract][Full Text] [Related]
8. Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction.
Kubota Y; Han Q; Masaki N; Hozumi C; Hamada K; Aoki Y; Obara K; Tsunoda T; Hoffman RM
Anticancer Res; 2022 Dec; 42(12):5819-5823. PubMed ID: 36456116
[TBL] [Abstract][Full Text] [Related]
9. Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells.
Ardjmand D; Kubota Y; Sato M; Han Q; Mizuta K; Morinaga S; Hoffman RM
Anticancer Res; 2024 Mar; 44(3):929-933. PubMed ID: 38423628
[TBL] [Abstract][Full Text] [Related]
10. Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
Han Q; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1921-1926. PubMed ID: 33813397
[TBL] [Abstract][Full Text] [Related]
11. The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-regulates the Expression of
Aoki Y; Kubota Y; Han Q; Masaki N; Obara K; Bouvet M; Chawla SP; Tome Y; Nishida K; Hoffman RM
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):679-685. PubMed ID: 38035708
[TBL] [Abstract][Full Text] [Related]
12. Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Tsunoda T; Hoffman RM
Anticancer Res; 2022 Aug; 42(8):3857-3861. PubMed ID: 35896248
[TBL] [Abstract][Full Text] [Related]
13. Recombinant-methioninase-producing
Kubota Y; Han Q; Morinaga S; Mizuta K; Bouvet M; Tsunoda T; Hoffman RM
Cancer Diagn Progn; 2023; 3(6):649-654. PubMed ID: 37927811
[TBL] [Abstract][Full Text] [Related]
14. Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Wu NF; Samonte C; Wu J; Hozumi C; Obara K; Kubota Y; Aoki Y; Miyazaki J; Hoffman RM
In Vivo; 2022; 36(6):2598-2603. PubMed ID: 36309364
[TBL] [Abstract][Full Text] [Related]
15. Development of Recombinant Methioninase for Cancer Treatment.
Hoffman RM; Tan Y; Li S; Han Q; Yagi S; Takakura T; Takimoto A; Inagaki K; Kudou D
Methods Mol Biol; 2019; 1866():107-131. PubMed ID: 30725412
[TBL] [Abstract][Full Text] [Related]
16. Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy.
Tan Y; Xu M; Tan X; Tan X; Wang X; Saikawa Y; Nagahama T; Sun X; Lenz M; Hoffman RM
Protein Expr Purif; 1997 Mar; 9(2):233-45. PubMed ID: 9056489
[TBL] [Abstract][Full Text] [Related]
17. Methionine Restriction: Ready for Prime Time in the Cancer Clinic?
Yamamoto J; Han Q; Simon M; Thomas D; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):641-644. PubMed ID: 35093861
[TBL] [Abstract][Full Text] [Related]
18. Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey.
Hoffman RM
Expert Opin Biol Ther; 2015 Jan; 15(1):21-31. PubMed ID: 25439528
[TBL] [Abstract][Full Text] [Related]
19. Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
Han Q; Tan Y; Hoffman RM
Anticancer Res; 2020 May; 40(5):2813-2819. PubMed ID: 32366428
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer.
Sato M; Han Q; Kubota Y; Baranov A; Ardjmand D; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Bouvet M; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Jan; 44(1):31-35. PubMed ID: 38159986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
